Screening for IA-2 and zinc transporter 8 antibodies identifies relatives of type 1 diabetic patients with a high and age-independent progression rate to clinical onset by Balti, E. V et al.
S 118 Diabetologia (2012) 55:[Suppl1]S1–S538
1 C
PS 001 Autoimmune diabetes
265
Vitamin D intake during childhood and advanced beta cell 
autoimmunity in young children with HLA-conferred susceptibility to 
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Background: Evidence for the role of vitamin D during childhood in the 
development of beta-cell autoimmunity and clinical diabetes is inconsistent.
Materials and methods: Two hundred seventy-four children with repeated 
positivity for antibodies against islet cells (ICA), together with positivity for 
at least one of the other three antibodies analyzed or clinical type 1 diabetes 
(a composite endpoint of advanced beta-cell autoimmunity) were identiﬁed 
from a prospective birth cohort of 7787 infants with HLA-DQB1-conferred 
susceptibility to type 1 diabetes born in 1996-2004. Three-day food records 
were completed by the families and day care personnel at 3 to 12 month in-
tervals. Four birth date, gender, area and genetic risk matched controls having 
been in the follow-up at least until the age when the case became a case were 
randomly selected for each case.
Results: The mean dietary intakes of vitamin D from diet and supplements 
for 3 and 6 month, 1, 2, 3, 4 and 6 year-olds were 10.4, 12.1, 11.1, 7.9, 5.9, 5.1 
and 6.3 μg/day, respectively. Vitamin D intake either from food (OR 1.08, 95% 
CI 0.97-1.20), supplements (OR 0.96, 95% CI 0.86-1.07) or the total dietary 
intake (OR 0.96, 95% CI 0.83-1.11) were not associated with advanced beta-
cell autoimmunity.
Conclusion: In relation to the nutrition recommendations the average in-
take of vitamin D was suboptimal among these children with HLA-conferred 
susceptibility to type 1 diabetes. The longitudinal vitamin D intake was not, 
however, related to the development of advanced beta-cell autoimmunity.
Clinical Trial Registration Number: NCT00223613
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Background and aims: The receptor for advanced glycation end products 
(RAGE) is a multiligand receptor involved in inﬂammatory and immune re-
sponses. RAGE is suggested to play a role both in the pathogenesis of type 
1 diabetes (T1D) and in the development of its complications. The circulat-
ing concentrations of soluble RAGE (sRAGE) may be reduced during acute 
autoimmune processes. This study set out to assess the dynamics of sRAGE 
during the preclinical T1D disease process.
Materials and methods: Serum levels of sRAGE were analyzed in 110 chil-
dren who progressed to T1D during prospective observation. Samples ana-
lyzed were taken at four diﬀerent time points: (1) before seroconversion to 
autoantibody positivity; (2) at the time of seroconversion to positivity for one 
autoantibody; (3) at the time of seroconversion to positivity for multiple (≥ 
2) autoantibodies; and (4) close to the diagnosis of T1D. Samples of 110 au-
toantibody-negative controls matched for age, sex, HLA-genotype and place 
of birth were analyzed for sRAGE at corresponding time points.
Results: The progressors had higher levels of sRAGE at all four time points, 
but the diﬀerence was signiﬁcant only in the ﬁrst and last sample [mean dif-
ference 172 pg/ml, p=0.01 and 164 pg/ml, p=0.02, respectively (t-test)]. There 
was a decline in the sRAGE levels in the progressors between the ﬁrst sample 
and the second sample [mean sRAGE 1400 pg/ml vs. 1251 pg/ml, p=0.001 
(paired t-test)]. A diﬀerence in the sRAGE concentrations was also seen when 
the ﬁrst sample was compared to the third sample (mean sRAGE 1402 pg/
ml vs. 1232 pg/ml, p<0.001). There was no such diﬀerence in sRAGE levels 
between the samples taken from the matched controls at corresponding time 
points. There were no signiﬁcant diﬀerences between the sRAGE levels at se-
roconversion and the concentrations at T1D diagnosis.
Conclusion: Prediabetic children seem to have higher circulating concentra-
tions of sRAGE when compared to controls. A reduction in the circulating 
sRAGE concentrations coincides with the appearance of diabetes-predictive 
autoantibodies in children progressing to overt T1D. Whether this reﬂects a 
damaging or attempted protective mechanism remains to be deﬁned.
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Background and aims: In ﬁrst-degree relatives of type 1 diabetic patients, we 
investigated whether diabetes risk assessment solely based on IA-2 and zinc 
transporter 8 antibody status (IA-2A, resp. ZnT8A) is as eﬀective as screen-
ing for autoantibodies (Abs) against insulin (IAA), GAD (GADA) and IA-2 
(with or without ZnT8A) in identifying children, adolescents and adults who 
rapidly progress to diabetes (within 5 years) in the perspective of constituting 
homogeneous risk groups for immune interventions before diabetes onset.
Materials and methods: Abs were determined by radiobinding assays dur-
ing follow-up of 6444 siblings and oﬀspring aged 0-39 years at inclusion and 
consecutively recruited by the Belgian Diabetes Registry.
Results: We identiﬁed 394 persistently IAA+, GADA+, IA-2A+ and/or ZnT8A+ 
relatives (6.1%). After a median follow-up time of 52 months, 132 relatives 
developed type 1 diabetes. In each age category tested (0-9 years, 10-19 years 
and 20-39 years) progression to diabetes was signiﬁcantly quicker in the pres-
ence of IA-2A and/or ZnT8A than in their joint absence. The 5-year pro-
gression rate was age-independent if IA-2A and/or ZnT8A were present at 
baseline but decreased with age if only GADA and/or IAA were detected (P 
= 0.008). Screening for IA-2A and ZnT8A alone identiﬁed 74% of the rapid 
progressors (vs. 65% if positive for ≥2 Abs among IAA, GADA and IA-2A) 
and reduced the group of high-risk Ab+ relatives to be followed by 63%. Posi-
tivity for IA-2A and/or ZnT8A was as sensitive as positivity for at least 2 out 
of 4 antibodies in individuals aged 10-39 years but less sensitive under age 10, 
an age group generally not considered for immune interventions until now.
Conclusion: Screening for IA-2A and ZnT8A alone allows to identify the 
majority of rapidly progressing prediabetic siblings and oﬀspring regardless 
of age and is more cost-eﬀective to select participants for intervention trials 
than conventional screening.
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